Gilead Sciences | Rentekostnader



Interest Expense On Debt Endring Dato
AbbVie USD 610M 19M 2024-12
Agios Pharmaceuticals 3.01M 10.05M 2024-12
ALKERMES USD 4.65M 1.35M 2024-12
Alnylam Pharmaceuticals USD 38.97M 4.6M 2024-12
Amgen USD 747M 29M 2024-12
Biogen USD 60M 200K 2024-12
BioMarin Pharmaceutical USD 2.58M 391K 2024-12
Bristol-Myers Squibb USD 496M 9M 2024-12
Eli Lilly USD 224.7M 78.4M 2024-12
Gilead Sciences USD 248M 10M 2024-12
GlaxoSmithKline 173M 17M 2024-12
Glaxosmithkline 178.05M 24.73M 2024-12
Incyte USD 419K 355K 2024-12
J&J USD 137M 56M 2024-12
Merck USD 328M 2M 2024-12
Moderna USD 6M 0 2024-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 275M 11M 2024-12
Pfizer USD 739M 45M 2024-12
PTC Therapeutics USD 42.11M 1.09M 2024-09
Regeneron Pharmaceuticals USD 10.5M 3.3M 2024-12
Sanofi 62M 17M 2024-12
Sarepta Therapeutics USD 4.92M 86K 2024-09
United Therapeutics USD 7.9M 2.2M 2024-12
Vertex Pharmaceuticals USD 2.8M 4.7M 2024-12



Gilead Sciences Rentekostnader - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Mar 2025.